华东医药董秘陈波：GLP-1受体激动剂HDM1002完成体重管理适应症临床III期研究首例受试者入组

Group 1 - The 2025 Zhejiang Listed Companies Investor Online Collective Reception Day and 2024 Annual Performance Briefing was held on May 13, 2025 [1] - East China Pharmaceutical's board secretary, Chen Bo, announced that the oral small molecule GLP-1 receptor agonist HDM1002 has completed the enrollment of the first subject in the Phase III clinical trial for weight management indication as of April 2025, with plans to complete all subject enrollments by the end of June 2025 [1] - The Phase II clinical trial for diabetes indication is progressing smoothly, with topline results expected in Q3 2025 and entry into Phase III clinical trials in the second half of 2025 [1] Group 2 - The GLP-1R/GIPR dual-target long-acting peptide agonist HDM1005 injection is currently undergoing Phase II clinical trials for weight management indication, having completed enrollment of all subjects in April 2025, with expectations to enter Phase III clinical trials in Q4 2025 [1] - The Phase II clinical trial for diabetes indication has also completed the enrollment of the first subject as of April 2025 [1] - During the reporting period, HDM1005 injection received NMPA approval for new indications, including treatment for obstructive sleep apnea (OSA) with obesity or overweight in adults and heart failure with preserved ejection fraction (HFpEF) with obesity or overweight in adults [1] Group 3 - The FGF21R/GCGR/GLP-1R tri-target agonist DR10624 injection is currently conducting Phase II clinical research in China for treating metabolic-associated fatty liver disease with high-risk liver fibrosis and metabolic-associated alcoholic fatty liver disease, having completed the enrollment of the first subject in April 2025 [2] - A previously initiated Phase II clinical study of DR10624 for severe hypertriglyceridemia in China has completed enrollment of all patients, with topline results expected in Q3 2025 [2] - DR10624's clinical trial applications for type 2 diabetes and weight indications have been approved in China, and key research data for DR10624 in treating obesity with hypertriglyceridemia was presented at the EASL Congress 2025 in Amsterdam [2]